X
1. 151266-23-8
2. 4-amino-3-iodo-1h-pyrazolo[3,4-d]pyrimidine
3. 4-amino-3-iodopyrazolo[3,4-d]pyrimidine
4. 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine
5. 1h-pyrazolo[3,4-d]pyrimidin-4-amine, 3-iodo-
6. 3-iodo-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine
7. Mfcd03787931
8. 3-iodo-1h-pyrazolo{3,4-d}pyrimidin-4-amine
9. Schembl8801
10. 7-iodo-7-deaza-8-aza-adenine
11. Dtxsid00364058
12. Bcp08713
13. Zinc5814210
14. Akos015853606
15. Cs-w009055
16. Pb15752
17. Sb21681
18. 1h-pyrazolo[3,4-d]pyrimidin-4-amine,
19. 3-iodo-4-aminopyrazolo[3,4-d]pyridine
20. 3-iodopyrazolo[3,4-d]pyrimidin-4-amine
21. 4-amino-3-iodopyrazolo[3,4-d]pyridine
22. Ac-26933
23. Am803252
24. As-20113
25. Sy007580
26. Db-006639
27. 3-iodo-4-amino-1h-pyrazolo[3,4-d]pyridine
28. Ft-0651030
29. I0941
30. 1h-pyrazolo[3,4-d]pyrimidin-4-amine,3-iodo-
31. 3-iodo-1h-pyrazolo[3,4-d]pyrimidine-4-amine
32. 3-iodo-4-amino-1h-pyrazolo[3,4-d]pyrimidine
33. 3-iodo-1h-pyrazolo [3, 4-d]pyrimidin-4-amine
34. A809151
35. W-201348
36. 3-iodo-1h-pyrazolo[3,4-d]pyrimidin-4-amine, Aldrichcpr
37. 3-iodo- 3-iodo-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine
| Molecular Weight | 261.02 g/mol |
|---|---|
| Molecular Formula | C5H4IN5 |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 0 |
| Exact Mass | 260.95114 g/mol |
| Monoisotopic Mass | 260.95114 g/mol |
| Topological Polar Surface Area | 80.5 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 154 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
List of SuppliersNote: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Market Place
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
